Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions... see more

Recent & Breaking News (NDAQ:FBIO)

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab

GlobeNewswire April 21, 2020

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency

GlobeNewswire April 20, 2020

Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire March 30, 2020

Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program

GlobeNewswire March 23, 2020

Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire March 16, 2020

Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire March 16, 2020

Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire March 11, 2020

Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment Option

GlobeNewswire February 24, 2020

Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106

GlobeNewswire February 18, 2020

Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA

GlobeNewswire February 13, 2020

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

GlobeNewswire February 11, 2020

Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

GlobeNewswire January 22, 2020

Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

GlobeNewswire January 16, 2020

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

GlobeNewswire January 13, 2020

Journey Medical Corporation Recaps 2019 Growth

GlobeNewswire January 13, 2020

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children's Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

GlobeNewswire December 23, 2019

Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol

GlobeNewswire December 11, 2019

Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference

GlobeNewswire December 2, 2019

Fortress Biotech to Participate in December 2019 Investor Conferences

GlobeNewswire December 2, 2019

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

GlobeNewswire November 25, 2019